Mireles R, Leppik I E
Epilepsia. 1985 Mar-Apr;26(2):122-6. doi: 10.1111/j.1528-1157.1985.tb05394.x.
The efficacy and the potential risk of inducing convulsive or nonconvulsive status epilepticus with the combination of valproate (VPA) and clonazepam (CZP), with or without other anticonvulsant drugs, in 55 patients with intractable epilepsy was evaluated. The patients were treated with VPA and CZP concomitantly for from 3 to 72 months (mean 21.7 months). Trough VPA serum levels ranged from 26 to 96 micrograms/ml). Trough CZP serum levels ranged from 5 to 63 ng/ml (mean 22.6 ng/ml). The treatment seizure frequency was compared with baseline values before combination treatment. Seizure improvement was obtained in 7 of 8 patients with absence seizures, 8 of 9 patients with myoclonic seizures, 19 of 39 patients with complex partial seizures, 3 of 14 patients with primary generalized tonic-clonic seizures, 8 of 23 patients with secondarily generalized tonic-clonic seizures, and 3 of 14 patients with atonic seizures. No single case of status epilepticus or exacerbation of seizures of any type was seen.
评估了55例难治性癫痫患者联合使用丙戊酸盐(VPA)和氯硝西泮(CZP),无论是否联用其他抗惊厥药物,诱发惊厥性或非惊厥性癫痫持续状态的疗效及潜在风险。患者接受VPA和CZP联合治疗3至72个月(平均21.7个月)。VPA血清谷浓度范围为26至96微克/毫升。CZP血清谷浓度范围为5至63纳克/毫升(平均22.6纳克/毫升)。将治疗后的癫痫发作频率与联合治疗前的基线值进行比较。8例失神发作患者中有7例发作改善,9例肌阵挛发作患者中有8例发作改善,39例复杂部分性发作患者中有19例发作改善,14例原发性全面强直阵挛发作患者中有3例发作改善,23例继发性全面强直阵挛发作患者中有8例发作改善,14例失张力发作患者中有3例发作改善。未观察到任何一例癫痫持续状态或任何类型癫痫发作的加重情况。